{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:09:03Z","timestamp":1792728543891,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jaip.2023.11.032","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T12:09:15Z","timestamp":1700914155000},"page":"562-568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The Role of Biologics in the Treatment of Food Allergy"],"prefix":"10.1016","volume":"12","author":[{"given":"Sayantani B.","family":"Sindher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Zuberbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Arasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-4256","authenticated-orcid":false,"given":"R. Sharon","family":"Chinthrajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.11.032_bib1","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 Oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.032_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1710-1492-10-1","article-title":"Safety and feasibility of oral immunotherapy to multiple allergens for food allergy","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","article-title":"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"4","author":"Hourihane","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jaip.2023.11.032_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jaip.2017.09.016","article-title":"Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial","volume":"6","author":"Bird","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.032_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100747","article-title":"Oral immunotherapy for food allergy: translation from studies to clinical practice?","volume":"16","author":"Pouessel","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2023.11.032_bib8","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1542\/peds.2011-0204","article-title":"The prevalence, severity, and distribution of childhood food allergy in the United States","volume":"128","author":"Gupta","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2023.11.032_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.anai.2018.04.020","article-title":"Development of a tool predicting severity of allergic reaction during peanut challenge","volume":"121","author":"Chinthrajah","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES randomized clinical trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2023.11.032_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.jaip.2022.05.015","article-title":"Peanut oral immunotherapy with or without H(1) and H(2) antihistamine premedication for peanut allergy (PISCES): a placebo-controlled randomized clinical trial","volume":"10","author":"Chu","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.anai.2022.07.033","article-title":"Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials","volume":"129","author":"Ciaccio","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib13","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib14","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines\u2014recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.11.032_bib15","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.032_bib16","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.11.032_bib17","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2023.01.007","article-title":"The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders","volume":"151","author":"Sindher","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib20","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstrom","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2023.11.032_bib21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.032_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaip.2023.11.032_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab","volume":"10","author":"Begin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A\u00a0phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jaip.2023.11.032_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2020.08.039","article-title":"Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients","volume":"147","author":"Azzano","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-020-00419-z","article-title":"Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy","volume":"16","author":"Langlois","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib28","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A\u00a0phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib30","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacig.2022.05.006","article-title":"on behalf of theOUtMATCH study team. Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)","volume":"1","author":"Wood","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Glob"},{"key":"10.1016\/j.jaip.2023.11.032_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaip.2022.10.022","article-title":"Retail food equivalents for post-oral immunotherapy dosing in the omalizumab as monotherapy and as adjunct therapy to multi-allergen oral immunotherapy in food-allergic children and adults (OUtMATCH) clinical trial","volume":"11","author":"Groetch","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib33","unstructured":"US Food and Drug Administration. Dupixent prescribing information (revised June 2022). Accessed December 13, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s042lbl.pdf"},{"key":"10.1016\/j.jaip.2023.11.032_bib34","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/all.15591","article-title":"Dupilumab has a profound effect on specific-IgE levels of\u00a0several food allergens in atopic dermatitis patients","volume":"78","author":"Spekhorst","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.11.032_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaip.2023.11.032_bib36","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1016\/j.jaip.2021.07.045","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy","volume":"9","author":"Corren","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.11.032_bib38","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jaip.2018.05.035","article-title":"Goals and motivations of families pursuing oral immunotherapy for food allergy","volume":"7","author":"Dunlop","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib39","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.11.032_bib40","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/all.15211","article-title":"Allergen immunotherapy and\/or biologicals for IgE-mediated food allergy: a systematic review and meta-analysis","volume":"77","author":"de Silva","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.11.032_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100682","article-title":"World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow\u2019s Milk Allergy (DRACMA) guideline update\u2014XIII\u2014oral immunotherapy for CMA\u2014systematic review","volume":"15","author":"Bognanni","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2023.11.032_bib42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jaip.2021.12.009","article-title":"Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective","volume":"10","author":"Soller","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.11.032_bib43","first-page":"1","article-title":"Efficacy of mepolizumab and omalizumab combination therapy in uncontrolled asthma","author":"Sezgin","year":"2023","journal-title":"J\u00a0Asthma"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823013016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823013016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T11:45:23Z","timestamp":1716032723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823013016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2213219823013016"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.11.032","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Biologics in the Treatment of Food Allergy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.11.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}